2 results found.

Progressive Hairy Cell Leukemia, Initial Treatment, Refractory Ha Clinical Trial using ibrutinib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia.
ibrutinib; laboratory biomarker analysis; pharmacological study

Leukemia, Hairy Cell Clinical Trial using moxetumomab pasudotox; IV Bag Protectant for Moxetumomab pasudotox

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia.
moxetumomab pasudotox; IV Bag Protectant for Moxetumomab pasudotox